12-Month Lobbying Summary - Organization

Canadian Generic Pharmaceutical Association (CGPA) / James Keon, President

Registration Summary

Currently active - Last Updated: 2023-11-27

Who is lobbying?

Canadian Generic Pharmaceutical Association (CGPA) (Address & business activities)

James Keon, President

Government Funding

Did Canadian Generic Pharmaceutical Association (CGPA) request or receive government funding within the last 12 months? No

Coalition Members Information

Canadian Generic Pharmaceutical Association (CGPA) is not a coalition member.

Direct Interests of the Lobbying Activity

Affiliates

Canadian Generic Pharmaceutical Association (CGPA) does not have any affiliates that could have a direct interest in the outcome of the lobbying activities

Other Affiliates

The activities of Canadian Generic Pharmaceutical Association (CGPA) are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking

Contributors with a Direct Interest in the Outcome

No person or organization contributed over $1000CDN, within the preceding 12 months, toward the lobbying activity on behalf of Canadian Generic Pharmaceutical Association (CGPA):

What is being lobbied?

Subject Matter of the Lobbying Activities

Details Regarding the Identified Subject Matter

Will any of the lobbyists listed within this registration arrange a meeting between a public office holder and any other individual for the purpose of attempting to influence any of the matters listed below:

Specific Topics of Lobbying Communications	Intended Outcomes	Associated Subject Matters
Accelerating listing of generic drugs through regulatory reform.	Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Addressing and minimizing use of brand coupon cards.	Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Addressing and minimizing use of brand coupon cards. Commencement of negotiations to renew Agreement with pan-Canadian Pharmaceutical Alliance, including potential framework on biosimilars.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
BC's biosimilar initiative and increasing market share of biosimilars products in British Columbia.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Commencement of negotiations to renew Agreement with pan-Canadian Pharmaceutical Alliance, including potential framework on biosimilars.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Discussions of British Columbia's position on the National Pharmacare initiative in a manner congruent with the interests of generic pharmaceutical manufacturers.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Encouraging British Columbia to direct the pan Canadian Pharmaceutical Alliance to negotiate a sustainable pricing regime with the generic manufacturing sector.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Expansion of reimbursement criteria by the Government of British Columbia for biosimilar products.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Improved demand forecasts and purchasing commitments from hospitals	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Decision by the Executive Council or a member of the Executive Council to have the private sector instead of the Crown provide goods or services to the government of British Columbia or a Provincial entity	Health
Maintenance of bilateral meetings between the Ministry of Health and the CGPA.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Measures to strengthen Canada's domestic pharmaceutical industry	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Promoting greater utilization of generic prescription medicines.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Provincial government policy on opioid prescribing and dispensing and proper role of generic manufacturers.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Requesting firm notification of price changes for generic products.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Support for CGPA pricing proposals in current negotiations with pan-Canadian Pharmaceutical Alliance for renewal of agreement with pCPA.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health
Support for concerns relating to Canadian-specific requirement for insulin pumps for use with Biosimilar products.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health

Gifts or benefits provided by the organization

Gifts or Benefits Provided to Public Officer Holders
Name	Gift or Benefit Description	Circumstance	Date Promised	Value Promised	Date Given	Value Given
No Records

Who is being lobbied?

Ministries/Provincial Entities

Health

Who are the lobbyists?

In-house Lobbyists

Lobbyist

Contributions

Jeff Connell
Subscribes to a Code of Conduct: No
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Jody Cox
Subscribes to a Code of Conduct: No
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: Yes

Political: No
Sponsorship: No
Recall: No

James Keon
Subscribes to a Code of Conduct: No
Former Public Office Holder in BC: No

Lobbied or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization, on or after 2020-09-21: Yes

Political: No
Sponsorship: No
Recall: No

Registration number: 1627-750
View all registrations versions

Lobbying Activity Reports

What lobbying activities have taken place in the last 12 months?

What lobbying activities have taken place in the last 12 months?
Date	Arranging a Meeting	Lobbyists	Senior Public Office Holder, Position Title \| Ministry/Provincial Entity	Subject Matters
2023-11-28	Yes	Jeff Connell , Jody Cox	Mitch Moneo, ADM, Ministry of Health, PLBSD - Pharmaceutical, Laboratory & Blood Services Division \| Provincial Health Services Authority	View
2023-11-28	Yes	Jeff Connell , Jody Cox	Shirley Bond, MLA for Prince George-Valemount \| Member(s) of the BC Legislative Assembly Ian Paton, MLA for Delta South \| Member(s) of the BC Legislative Assembly	View
2023-11-27	Yes	Jeff Connell , Jody Cox	Alison Copeland, Senior Advisor \| Minister's Office, Health Adrian Dix, Minister of Health \| Health Mitch Moneo, ADM, Ministry of Health, PLBSD - Pharmaceutical, Laboratory & Blood Services Division \| Provincial Health Services Authority	View
2023-08-28	No	James Keon	Mitch Moneo, Assistant Deputy Minister \| Pharmaceutical, Laboratory & Blood Services Division, Health	View
2023-05-29	No	James Keon , Jody Cox	Mitch Moneo, Assistant Deputy Minister \| Pharmaceutical, Laboratory and Blood Services Division, Health	View

View all Lobbying Activity Reports

Canadian Generic Pharmaceutical Association (CGPA) - Address & business activities

Address:

4100 Yonge Street
Suite 501
Toronto, ON M2P 2B5
Canada

Telephone number: 416-223-2333

Fax number: 416-223-2425

Contact information in previous versions
- 4100 Yonge Street
  Suite 501
  Toronto, BC M2P 2B5
  Canada
  
  Telephone number: 416-223-2333
  
  Fax number: 416-223-2425
- 4120 Yonge Street
  Suite 501
  Toronto, BC M2P 2B5
  Canada
  
  Telephone number: 416-223-2333
  
  Fax number: 416-223-2425
- 4120 Yonge Street
  Suite 409
  Toronto, BC M2P 2B8
  Canada
  
  Telephone number: 416-223-2333
  
  Fax number: 416-223-2425
- 4120 Yonge Street
  Suite 409
  Toronto, ON M2P 2B8
  Canada
  
  Telephone number: 416-223-2333
  
  Fax number: 416-223-2425

Description of Activities:
The CGPA's mission is to promote an environment which supports and enhances the provision of affordable generic and biosimilars medications to Canadians and patients around the world. The Association researches and develops positions regarding a wide variety of policies, regulations and legislation that affects our member companies. We promote our sector's interests by publishing material as well as directly contacting government officials, the media and other opinion leaders and decision makers.

Descriptions of the organization's activity in previous versions:
- The CGPA's mission is to promote an environment which supports and enhances the provision of affordable generic medications to Canadians and patients around the world. The Association researches and develops positions regarding a wide variety of policies, regulations and legislation that affects our member companies. We promote our sector's interests by publishing material as well as directly contacting government officials, the media and other opinion leaders and decision makers.

Date Modified:: 2024-01-29

Menus

www.lobbyistsregistrar.bc.ca

12-Month Lobbying Summary - Organization

Canadian Generic Pharmaceutical Association (CGPA) / James Keon, President

Who is lobbying?

Canadian Generic Pharmaceutical Association (CGPA) (Address & business activities)

Government Funding

Coalition Members Information

Direct Interests of the Lobbying Activity

Affiliates

Other Affiliates

Contributors with a Direct Interest in the Outcome

What is being lobbied?

Details Regarding the Identified Subject Matter

Gifts or benefits provided by the organization

Who is being lobbied?

Ministries/Provincial Entities

Who are the lobbyists?

What lobbying activities have taken place in the last 12 months?